ASOA Gold Partner - Omeros

Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics targeting complement-mediated diseases, CNS disorders, and immune-related diseases for large-market as well as orphan indications. Its marketed ophthalmic drug OMIDRIA® (phenylephrine/ketorolac intraocular solution) 1%/0.3% is the first and only FDA-approved drug of its kind. With two FDA breakthrough therapy designations, Omeros has multiple Phase 1, 2 and 3 clinical-stage programs focused on complement-mediated disorders and substance abuse, a large and diverse group of preclinical programs including GPR174, a novel immuno-oncology target that controls a newly discovered cancer immunity axis, and a novel antibody-generating platform.